Curriculum Vitae

Philip A. Levin, MD
Bay West Endocrinology Associates
MODEL Clinical Research, Senior Director

Date October 30, 2019

Contact Information

Business Address:	MODEL Clinical Research/Bay West Endocrinology Associates 6535 North Charles Street, suite 400 N Baltimore, Maryland 21204
Business Phone Number:	(443)524-1789 or (410)828-7417
Fax:	(410)828-0152
Email:	pal3420@yahoo.com

Education

1970	B.A., University of Virginia (Magna Cum Laude)
1974	M.D., University of Maryland

Post Graduate Education and Training

1974-1977	Internship/Residency, Yale-New Haven Hospital & Affiliates, School of Medicine, Medicine PG I, PG II, Pathology
1977-1978	Residency, Georgetown University Hospital, Medicine PG III
1978-1980	Fellowship, Endocrine,The Ohio State University Hospital
1980- 1982	NIH Clinical Associate, National Institute of Aging- Metabolism

Certifications

1975	Board Certified- Internal Medicine, Maryland
1978	Board Certified- Internal Medicine, Ohio
1978	Diplomat, American Board of Internal Medicine
1981	Board Certified- Endocrinology and Metabolism- A.B.I.M.

Medical Licensures

1975	Active	Maryland
1978	Inactive	Ohio

Employment History

Academic Appointments

1980- 1982	Instructor in Medicine, Johns Hopkins University, School of Medicine
1982- 1989	Assistant Professor, University of Maryland, School of Medicine
1989- 1994	Associate Professor, University of Maryland, School of Medicine
2000- 2008	Associate Clinical Professor, Division of Endocrinology, University of Maryland, School of Medicine
2011- present	Assistant Professor of Medicine, Johns Hopkins University School of Medicine
8/2017- present	Adjunct Associate Professor, University of Maryland, School of Medicine

Professional Society Membership

1994- 1996	General Member, American Medical Association
1994- 2000	General Member, The Endocrine Society
1994- present	Professional Section Member, Complications Committee, American Diabetes Association
2008- present	General Member, Americian Association of Clinical Endocrinologists
2009- 2010	General Member, American Federation for Clinical Research
2010- 2017	Executive Committee, Johns Hopkins Clinical Research Network, Johns Hopkins Medical Institution

Clinical Activities

Clinical Expertise

Board Certified Endocrinologist
Additional board certification in the sub specialty of endocrinology and metabolism
Research focus in the area of endocrinology and metabolism

Institutional Service

2014- present Chairman, Greater Baltimore Medical Center Institutional Review Board

Local and National Service

2009- present Consultant, Endocrine and Diabetes

Teaching Service

1982- 1985	Consultant Attending Division of Endocrinology- Department of Medicine University of Maryland School of Medicine
2000- 2008	Medical House Staff Attending Rounds Teaching Conferences Mercy Hospital
2009- present	Medical House Staff Noon Teaching Greater Baltimore Medical Conference Center

Grant Support

Active Grants

2004- present TrialNet Natural History Study of the Development of Type 1 Diabetes, NIH

2012- present A large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease (Randomized EValuation of the Effects of Anacetrapib through Lipid-modification) , CTSUREVEAL1; HPS 3 / TIMI 55: REVEAL
Merck

2014- present Co- Investigator: A Case - Finding Approach to Screening for Monogenic Diabetes, National Human Genome Research Institute (NHGRI), NIH, Principal Investigator: Toni Pollin, MS, PhD

2015- present PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Natural History Registry for Patients with Chronic Hypoparathyroidism, PAR-R13-001
NPS Pharmaceuticals, Inc.

2016- present Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk Open Label Extension, Fourier OLE Study
Amgen

2016- present Getting to an imprOved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia management (GOULD): a Registry of High Cardiovascular Risk Subjects in the United States
Amgen

2017- present A digital health tool for insulin titration (DHIT) for individuals with type 2 diabetes: a prospective outcomes study with a retrospective control group
iSage Rx, Inc.

2018- present Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients, Mannkind

2018-present Continuous Glucose Monitoring and Management In Type 2 Diabetes: COMMITED PTL-903076
Dexcom

2018-present A Randomized, Multicenter, Open-Label, Parallel-Group Clinical Study Comparing the Safety and Efficacy of MYL-1601D with NovoLog® in Type 1 Diabetes Mellitus Patients: MYL-1601D-3001
Mylan

Completed Grants

1983-1985 Glipizide Sulfonylurea, Phase II Trial
Pfizer Pharmaceuticals

1986- 1993 Diabetes Control and Complications Trial
NIH

1997- 2002 Osteoporosis Studies on Ibandronate
Roche Pharmaceuticals

1997- 2003 Evista Studies
Eli Lilly Pharmaceuticals

1999 Diabetes Control and Lipids Study
Parke-Davis

2000- 2005 Insulin Lispro Low Mixture Plus Metformin Compared to NPH Insulin Plus Metformin in Subjects with Type 2 Diabetes
Eli Lilly

Rosiglitazone Monotherapy compared to Metformin or Glyburide in Type 2 Diabetics
Glaxo SmithKline

Pioglitizone vs. Rosiglitazone in Type 2 Diabetics
Eli Lilly

Omapatrilat Cardiovascular Treatment Assessment vs. Enalipril
Bristol-Myers Squibb

Synthetic 10-Component Conjugated Estrogen vs. Placebo for Prevention of Osteoporosis in Hysterectomized, Postmenopausal Women
Endeavor Pharmaceuticals

Oral Insulin Spray studies
Generex Pharmaceuticals

Sub Investigator: Comparing effects of Carvedilil and Metoprolol on Glycemic Control in Hypertensive and Type II Diabetes Mellitus Patients, Principal Investigator: James H. Mersey, MD
SmithKline Beecham

Comparing Celecoxib, Rofecoxib and Naproxen in Hypertensive Patients with Osteoarthritis and Type II Diabetes Mellitus
Pharmacia

Placebo Controlled Dose Finding Study of KAD-1229 in Type II Diabetic Patients
Kissei Pharmaceuticals

Sub Investigator: Open Label Trial to Assess Noninferiority Between Pre and Post-meal Administration of HMR 1964 and Pre-meal Regular Human Insulin in Type I Diabetes Mellitus Patients Receiving Insulin Glargine as the Basal Insulin therapy, Principal Investigator: James H. Mersey, MD
Aventis Pharmaceuticals,

Sub Investigator: The Impact of Medical Subspecialty on Patients Compliance to Treatment, Principal Investigator: James H. Mersey, MD
Kos/Dupont Pharmaceuticals

Sub Investigator: Comparing HMR 1964 with Regular Human Insulin Injected Subcutaneously in Subjects with Type 2 Diabetes Mellitus Also Using NPH Insulin, and Which Will Lead into a Comparative 26 Week Safety Extension Study, Principal Investigator: James H. Mersey, MD
Aventis Pharmaceuticals

Sub Investigator A Randomized, Double- Blind, Dose Ranging, Dose Comparison- Controlled Trial to Determine the Safety and Efficacy of BMS-298585 in Subjects with Type 2 Diabetes, Principal Investigator: James H. Mersey, MD
Bristol-Myers Squibb

Sub Investigator: The Safety and Efficacy of Omapatrilat Modified Release Formulation in Subjects with Mild to Moderate Hypertension, Principal Investigator: James H. Mersey, MD
Bristol-Myers Squibb

Sub Investigator: Evaluation of Diabetic Retinopathy Progression in Subjects with Type 2 Diabetes Mellitus Treated with Insulin,
Principal Investigator: James H. Mersey, MD
Aventis Pharmaceuticals

Sub Investigator: Simvastatin and Fenofibrate Efficacy Trial,
Principal Investigator: James H. Mersey, MD
Merck and Co

Sub Investigator: A Randomized Trial of an Angiotensin II Receptor Antagonist (Telmisartan) and an ACE-Inhibitor (Ramipril) in Patients at High Risk for Cardiovascular Events and a parallel study, Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease,
Principal Investigator: James H. Mersey, MD
Boehringer Ingelheim

Evaluating the Efficacy and Safety of Tolterodine versus Placebo in the Treatment of Urinary Urgency and Frequency
Pharmacia

Comparing 3 Doses of Conjugated Estrogens with Placebo in Hysterectomized Postmenopausal Women for the Prevention Of Osteoporosis
Endeavor Pharmaceuticals

Comparing a Stratified Care Treatment Regimen versus Standard Therapy for the Acute Treatment of Migraine Headaches
Astra Zeneca

Comparing the Effects of Lotrel to Amlodipine and Benazepril on Systolic Blood Pressure and Pulse Pressure in Patients with Systolic Hypertension, Principal Investigator: James H. Mersey, MD
Novartis Pharmaceuticals

Sub Investigator: Correction of Hemoglobin and Outcomes in Renal Insufficiency, Principal Investigator: James H. Mersey, MD
Ortho Biotech

Improvement of Brittle Diabetes Control After Switching to Insulin Glargine from NPH Insulin: A Continuous Glucose Monitoring System
Aventis

The Effect of LY333531 on Albuminuria in Patients with Type 2 Diabetes
Eli Lilly and Company

Treatment of Peripheral Neuropathy in Patients with Diabetes: A Phase 3 Pivotal Clinical Trial
Eli Lilly and Company

Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes
Eli Lilly and Company

A Double-blind, Multi-center, Randomized, Placebo-controlled, Parallel Group Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients with Mild to Moderate Hypertension
Bertek

A Multi-center, Parallel Group Extension Study to Determine the Safety and Efficacy of Long-Term Nebivolol Exposure in Patients with Mild to Moderate Hypertension
Bertek

A Double-blind, Multi-center, Randomized, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients with Mild to Moderate Hypertension
Bertek

A Multi-center, Randomized, Double-blind, Double-dummy Study Evaluating the Safety and Efficacy of the Addition of Amlodipine to Quinapril or Losartan in the Treatment of Diabetic Hypertensive Subjects
Pfizer

A One Year, Open, Randomized, Parallel, Three-Arm Study Comparing Exubera vs. Avandia as Add on Therapy vs, Exubera Substitution of Sulfonylurea in Patients with Type 2 Diabetes, Poorly Controlled on Combination Sulfonylurea and Metformin Treatment
Pfizer

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Dose-Range Finding Study of Once Daily Dosing of L-000224715 in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
Merck

Assessment of Biomarkers in Diabetes
Hoffmann-La Roche

A Phase 3B, Multi-Center, Open Label Study Investigating the Clinical Utility and Safety of Pramintide in Subjects with Type 1 and Type 2 DiabetesMellitus Who Have Not Achieved Glycemic Targets with Insulin Therapy
Amylin

The Global Hypopituitary Control and Complications Study (HypoCCS)
Lilly

APIDRA Administered in a Fixed Bolus Regimen vs. a Variable Bolus Regimen Based on Carbohydrate Counting in Adult Subjects with Type 2 Diabetes Receiving Lantus as Basal Insulin: A Multicenter, Randomized, Parallel Open Label Clinical Study
Aventis

Effects of Arzoxifene on Vertebral Fracture Incidence and on Invasive Breast Cancer Incidence in Postmenopausal Women with Osteoporosis or with Low Bone Density
Lilly

Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group Evaluation of the Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily Compared with Atorvastatin Alone, on the Occurrence of Major Cardiovascular Events in Subjects with Coronary Heart Disease or Risk Equivalents
Pfizer

3S Confidence Glucose Monitoring System Alternate Site (Forearm) Capillary Evaluation
Roche

TrialNet Natural History Study of the Development of Type 1 Diabetes, NIH Baltimore-Washington Major Affiliate
NIH

2006

Type 1 Diabetes Genetics Consortium
NIH, NIDDK, JDRF

A Prospective Randomized Trial Of The Cost Effectiveness Of Lantus Plus Apidra Compared To Premix Analog Insulin Regimens In Patients With Type 2 Diabetes (Lace)
sanofi aventis

Pulmonary Outcomes within a 2 Year Period in Subjects with Diabetes Mellitus Treated with Technosphere Insulin or Usual Antidiabetic Treatment, Mannkind

A Double-Blind, Multi-Center, International (US and Europe), Randomized, Placebo-Controlled Study of Safety and Efficacy of Trospium Chloride 60 Mg Modified Release Capsules Versus Placebo, Once Daily, For 12 Weeks Followed By a 9-Month, Open-Label Treatment Phase In Patients With Overactive Bladder
Indevus

The Durability of Twice-Daily Insulin Lispro Low Mixture Compared to Once-Daily Insulin Glargine when added to Existing Oral Therapy in Patients with Type 2 Diabetes and Inadequate Glycemic Control
Lilly

Effects of NovoLog® Mix 70/30 (biphasic insulin aspart 70/30) BID and QD vs. Byetta ™ (exenatide) BID on Glycemic Control: A Multicenter, 24-Week, Open-Label, Parallel Group Study in Patients with Type 2 Diabetes Mellitus not Achieving Glycemic Targets with Metformin and a Sulfonylurea
Novo Nordisk

A Phase 2a, Randomized, Double-blind, Placebo-controlled, Multi-Center Study to Examine Safety and Establish Proof of Concept with PHX1149 in Patients with Type 2 Diabetes Mellitus
Phenomix

A Phase 3, Open-Label, Parallel-Group Study to Evaluate the Efficacy of Preprandial Human Insulin Inhalation Powder (HIIP) Compared to Preprandial Injectable Insulin in Patients with Type 1 Diabetes Mellitus
Lilly

GOLD (ACCU-CHEK® Performa) Glucose Monitoring System Alternate Site Capillary Evaluation
Roche

A Phase 3, Open-Label, Three-Group Parallel Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) in Patients with Type 2 Diabetes Treated with Once-Daily Insulin Glargine
Lilly

Lipid Treatment Assessment Project
Pfizer

A 2-Year, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study To Evaluate The Long-Term Efficacy And Safety Of CP-945,598 In The Treatment Of Obese Subjects
Pfizer

A 1-Year, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study To Evaluate The Efficacy And Safety Of CP-945,598 In The Treatment Of Overweight, Oral Agent-Treated Subjects With Type 2 Diabetes Mellitus, Pfizer

2007 A study to compare Exubera inhaled insulin with injectable insulin
Pfizer

A Prospective, Randomized, Naturalistic Study Using Insulin Glargine or Detemir to Treat Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Medications Alone
sanofi aventis

An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAJECT and Regular Human Insulin in Patients with Type 1 Diabetes Mellitus
Biodel

Correlation Between the TCF7L2 Test and Diabetes Drug Response in Type 2 Diabetics
deCode Genetics

2008 A Double-Blind, Randomized, Placebo-Controlled, 5-Arm Titration Study to Evaluate the Efficacy and Safety of TAK-491 When Compared With Valsartan and Olmesartan in Subjects With Essential Hypertension
Takeda

A multi-centre, randomised, open-label, cross-over study to explore effectiveness, safety and preference of a new disposable pen PDS290 vs. FlexPen® in subjects with type 1 or type 2 diabetes
Novo Nordisk

Freedom 9 mm (ACCU-CHEK® Aviva) Glucose Monitoring System Alternative Site Capillary Evaluation
Roche

Freedom 7mm (ACCU-CHEK® Performa) Glucose Monitoring System Patient vs Techncian Capillary Evaluation
Roche

A Multicenter, Randomized, Placebo-Controlled, "Factorial" Design, 12-Month Study To Evaluate The Efficacy And Safety Of AVE5530 25 Mg/Day And 50 Mg/Day Co-Administered With All Registered Atorvastatin Strengths Ranging From 10 Mg To 80 Mg In Patients With Primary Hypercholesterolemia
sanofi aventis

A 12-Week, Double-Blind, Placebo-Controlled Trial of LY2428757 in Patients with Type 2 Diabetes Mellitus
Eli Lilly

The Effect Of Insulin Detemir In Combination With Liraglutide And Metformin Compared To Liraglutide And Metformin In Subjects With Type 2 Diabetes. A 26-Week, Randomised, Open-Label, Parallel-Group, Multicentre, Multinational Trial With A 26-Week Extension
Novo Nordisk

A Retrospective Clinical Practice Evaluation Of Lantus Cost Effectiveness Compared To Levemir In Diabetes Patients (Lace 2 Pilot Study)
sanofi Aventis

2009

LACE EMR Multi-Site Study - A Retrospective Clinical Practice Evaluation Of Lantus Cost-Effectiveness Compared To Levemir In Insulin-Naïve Type 2 Diabetes Patients (Insulin Naïve EMR Study)
sanofi aventis

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Dutogliptin in Patients with Type 2 Diabetes Mellitus on Background Treatment with Glimepiride with or without Metformin
Forest Research

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Dutogliptin in Patients with Type 2 Diabetes Mellitus on Background Treatment with Pioglitazone
Forest Research

Glycemic Effects Of Nebivolol Compared With Metoprolol Extended Release And Compared With Hydrochlorothiazide In Hypertensive Patients With Type 2 Diabetes Mellitus: A Pilot Study, NEB-MD-19
Forest Research

A Trial Comparing Efficacy And Safety Of NN5401 With Insulin Glargine, Both In Combination With Oral Antidiabetic Drugs In Subjects With Type 2 Diabetes - NN5401-3593
Novo Nordisk

Accu-Chek Aviva Glucose Monitoring System Alternative Site Capillary Evaluation Patient vs. Technician, D8026-09-32
Roche

A Phase 2 Study of LY2605541 Compared with Insulin Glargine in the Treatment of Type 2 Diabetes Mellitus - I2R-MC-BIAC
Eli Lilly

A Phase 2 Study of LY2605541 Compared with Insulin Glargine in the Treatment of Type 1 Diabetes Mellitus - 12R-MC-BIAD
Eli Lilly

A 26-Week, Randomised, Controlled, Open Label, Multicentre, Multinational, Three-Arm, Parallel, Treat-To-Target Trial Comparing Efficacy And Safety Of Two Different Dosing Regimens Of SIBA And One Dosing Regimen Of InsulinGlargine, Both In Combination With Meal-Time Insulin Aspart In Subjects With Type 1 Diabetes Mellitus - NN1250-3770
Novo Nordisk

2010 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study To Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide In Type 2 Diabetic Patients After An Acute Coronary Syndrome - EFC11319
sanofi aventis

Sub Investigator: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate The Effect Of 5 Mg Or 20 Mg Nebivolol Once Daily On Blood Pressure N Patients With Systolic Stage 2 Hypertension, NEB-MD-20, Principal Investigator: James H. Mersey, MD
Forest Research

A Randomized, Double-Blind, Parallel-Group Study To Evaluate The Effects Of First Line Treatment With A Free Combination Of Nebivolol And Lisinopril Compared With Placebo And The Monotherapy Components On Blood Pressure In Patients With Stage 2 Diastolic Hypertension, NEB-MD-25
Forest Research

Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events
Novo Nordisk

Protocol #: D8026-10-17 Freedom II 7 mm (ACCU-CHEK® Performa) Test Strip with the ACCU-CHEK® Performa Glucose Monitoring System (Alternative Site Capillary Evaluation)
Roche Diagnostics

2011 An open label randomized multicenter study to assess patient preference for and evaluate clinical benefit of insulin glargine (Lantus®) SoloSTAR® pen versus conventional vial/syringe method of insulin glargine (Lantus®) injection therapy in patients with type 2 diabetes mellitus, Lantu L 05191
sanofi aventis

2012 Effectiveness of V-Go™ for Patients with Diabetes in a Real-world Setting: A Long-term, Prospective, Observational Registry (SIMPLE) Study, V4006
Valeritas

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Safety and Insulin-Sparing Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Alone or in Combination With Metformin, MK-0431, Protocol 260
Merck

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With Statin Therapy In Patients with Clinically Evident Cardiovascular Disease, AMG 145 20110118
Amgen

Glycemia in Diabetic Elders (GLiDE) Trial
Johns Hopkins Clinical Research Network

2013

Protocol D01792.01-12-07 ACCU-CHEK® Aviva (No Code) Glucose Monitoring System with the ACCU-CHEK® Aviva Plus Test Strip ISO 15197 Section 8 User Performance Evaluation
Roche

Protocol D01792.01-12-08 ACCU-CHEK® Aviva (No Code) Glucose Monitoring System with the ACCU-CHEK® Aviva Plus Test Strip Alternative Site Capillary Evaluation
Roche

Sub Investigator: A Phase III Clinical Trial to Study the Safety and Efficacy of K-1293 Compared to Lantus™ in Subjects with Type 1 Diabetes Mellitus
Principal Investigator: James H. Mersey, MD
Merck, Sharp and Dohme Corporation

Efficacy and Safety of FIAsp compared to insulin aspart both in Combination with insulin detemir in Adults with Type 1 Diabetes Onset® 1
Novo Nordisk

2014

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events (MACE) in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR/Bupropion SR (LIGHT Study)
Parexel Orexigen

A randomized, double-blind, placebo-controlled, event driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP, CACZ885M2301
Novartis

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment with BELVIQ (lorcaserin HCl) of the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors APD356-G000-401, Eisai

NIH: A Case - Finding Approach to Screening for Monogenic Diabetes, National Human Genome Research Institute (NHGRI), Co- Investigator

2015 BI1245.72: A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 26 weeks in patients with Type 1 Diabetes Mellitus (EASE-3), Boehringer Ingelheim

NN1218-4131: Efficacy and Safety of Faster-acting Insulin Aspart compared to NovoRapid® both in combination with Insulin Degludec in Adults with Type 1 Diabetes, Novo Nordisk

2016 Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment, NN9924-4234 (PIONEER) Novo Nordisk

2017 A randomized, double-blind, placebo-controlled, event driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP, Open Label Extension CACZ885M2301 Novartis

Efficacy and Safety of Semaglutide once weekly versus placebo as add-on to SGLT-2i in subjects with type 2 diabetes mellitus, NN9535-4269 Novo Nordisk

A randomized, double-blind, dose finding study to evaluate the change in weight after 24 weeks treatment with 8 doses of LIK066 compared to placebo in obese or overweight adults, followed by 24 weeks treatment with 2 doses of LIK066 and placebo, CLIK066 Novartis

2018 A Randomized, Multi-center, Double-Blind, Parallel-Group Clinical Study Comparing the Efficacy and Safety of MYL-1501D Produced by 2 Manufacturing Processes in Type 1 Diabetes Mellitus Patients, Mylan

Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients Mannkind

Continuous Glucose Monitoring & Management In Type 2 Diabetes: The COMMITED Study Dexcom

2019 A Randomized, Multicenter, Open-Label, Parallel-Group Clinical Study Comparing the Safety and Efficacy of MYL-1601D with NovoLog ® in Type 1 Diabetes Mellitus Patients Mylan

A Post- Approval Study to Demonstrate the Long-term Safety and Effectiveness of the Eversense Continuous Glucose Monitoring(CGM) System Senseonics, Inc.

Publications

1. Levin, P.A. and Falko, J.M.: Benign Parotid Enlargement in Bulimia. Ann.Int.Med., 92:877-830, 1980.

2. Levin, P.A. and Marlarkey, W.B.: Daughters of Women with Breast Cancer Have Elevated Mean 24-Hour Prolactin Levels and a Partial Resistance of PRL to Dopamine Suppression. J. Clin. Endocrinology Metab, 53:179-184, 1981.

3. Levin, P.A., Jenda, J.K., Joseph, J.A., Ingram, D.K. and Roth, G.S.: Dietary Restriction Retards Age-Associated Loss of Rat Striatal Dopamine Receptors. Science 214-561-526, 1981.

4. Levin, P.A., Heji, M., Joseph, J. and Roth, G.S.: Effects of Aging on Prolactin Regulation of Rat Striatal Dopamine Receptor Concentrates. Life Sci. 32:1743-49, 1983.

5. Levin, P.A., Falko, J.M., O'Doriaio, T.M. and Cataland, S.: Limitations of Single Dose Intermediate Acting Insulin: A Rapid Response Pattern in Some Type 1 Diabetics. Am.J.Med.Sci., 286:11-16, 1983.

6. Potter, J.F., **Levin, P.A.**, Anderson, R.A., Freiberg, J.M., Andres, R. and Elehi, D.: Glucose Metabolism in Glucose Intolerant Older People During Chronium Supplementations. Metabolism 3:199-204, 1985.

7. Zadik, Z., **Levin, P.A**. and Kowarski, A.A.: The Diagnostic Value of the 24-Hour Integrated Concentration of Plasma Aldosterone, Clin. Exper. Hypertension: Theory Practice A7(9): 1233-1242, 1985.

8. Hamlyn, J.M., Levinson, P.D., Ringel, R., **Levin, P.A.**, Hamilton, B.P., Blaustein, M.P., and Kowarski, A.A.: Relationships Among Andogenous Digitalis-Like Factors in Essential Hypertension. Fed. Proc. 44:3782-2788, 1985.

9. Chalew, S.A., Koetter, H., Hoffman, S., **Levin, P.A.**, and Kowarski, A.A.: Diagnosis of Reactive Hypoglycemia: Pitfalls in the Use of the Oral Glucose Tolerance Test. Southern Med.J., 79:285-287, 1986.

10. Adashi, E., and **Levin, P.A.**: Pathophysiology and Evaluation of Adrenal Hyperandrogenism. S.Paroduct Endocrinol 4:2, 155-177, 1986.

11. Zedik, Z., **Levin, P.A.**, Hamilton, B.P., and Kowersid, A.A.: Detection of Mild Primary Aldosteronism by the 6-Hour Integrated Aldosterone/Renin Ratio. Hypertension, 8:285-289, 1986.

12. Chalew, S.A., Armour, K.M., **Levin, P.A.**, Thorner, M.O., and Kowarski, A.A.: Growth Hormone Response to GHRH in Children with Subnormal Integrated Concentrations of Growth Hormone. J.Clin.Endocrinol Metab., 62:1110-1115, 1986.

13. Levin, P., The DCCT Research Group: Effects of Age, Duration and Treatment of Insulin-Dependent Diabetes Mellitus on Residual B-Cell Function: Observations During Eligibility Trial (DCCT). J.Clin. Endocrinol Metab., 85:30-36, 1987.

14. Levin, P.A., Chalew, S.A., Martin, L. and Kowarski, A.A.: Comparison of Assays for Growth Hormone Using Monoclonal or Polyclonal Antibodies for Diagnosis of Growth Disorders. J. Clin. Lab Med., 109:85-88, 1987.

15. Levin, P., Javonovic, L., Chalow, S., Martin, L., Pitarra, D., Kim, F. and Kowarski, A.: Linogliride Turnarate, Representing a New Class of Oral Hypoglycemic Agent for Diabetes. Clin. Phar. Therapy (Nov.)42:498-503, 1987.

16. Levin, P., The DCCT Research Group: Feasibility of Centralized Measurements of Glycated Hemoglobin in the Diabetes Control and Complications Trial: A Multicenter Study. Clin. Chemistry 33-2267-2271, 1987.

17. Grace, T., Shin, P., **Levin, P.**, and Stone, H.: Trauma Induced Hypokatemia. Quart J.Trauma 5:50-58, 1988.

18. Marsey, J.H., Cabellos, L., **Levin, P.A.**, and Bunky, S.: Estrogen Secreting Adrenal Tumor Responsiveness to ACTH. Localization by Adrenal Venous Sampling. So. Med. J. 81:275-278, 1988.

19. Levin, P., The DCCT Research Group: Factors in Development of Diabetic Neuropathy. Diabetes. 37:476-481, 1988.

20. Bistritzer, T., **Levin, P.A.**, Roeder, L.M., and Kapcala, L.P.: Differential Effects of Adrenocorticotropin(1-24) on 3H-2-Deoxy-D-Glucose Uptake in Cultured Cells Derived From Different Brain Regions. Neuroscience Letter 93-79-84, 1988.

21. Levin, P., The DCCT Research Group: Implementation of a Multicomponent Process to Obtain Informed Consent in the DCCT. Controlled Clinical Trials 10:83-96, 1989.

22. Levin, P.A., Bietritzer, T., Max, S.R., Hartukoglu, A., and Roeder, L.M.: ACTH 1-24 Stimulates Muscle Cell Glucose Uptake. Hor. Metab. Res., 22:808-611, 1990.

23. Levin, P., The DCCT Research Group: Diabetes Control & Complications Trial (DCCT) Update. Diab. Care 13:427-433, 1990.

24. Biatritzer, T., Roeder, L., Hanukoglu, L., and **Levin, P.**: Non-Insulin Dependent Diabetic Patients Have Increased Glucose Uptake in Red Blood Cells. Hor. Metab. Res. 23:70-73, 1991.

25. Levin, P., The DCCT Research Group: Lipid and Lipoprotein Levels in Patients with IDDM. Diab. Care 7:886-894, 1992.

26. Levin, P., The DCCT Research Group: The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin Dependent Diabetes. N.Eng.J.Med., 329:977-986, 1993.

27..Levin, P.A., The DCCT Research Group: Effect of Intensive Therapy on the Development and Progression of Diabetic Nephropathy in the Diabetes Control and Complications Trial. Kidney-Int., 47(6):1703-20, June 1995.

28. Levin, P.A., The DCCT Research Group: Progression of Retinopathy with Intensive Versus Conventional Treatment in the Diabetes Control and Complications Trial. Ophthalmology, 102(4):647-61, April 1995.

29. Levin, P.A., The DCCT Research Group: The Relationship of Glycemic Exposure (HgbA1C) to the Risk of Development and Progression of Retinopathy in the Diabetes Control and Complications Trial. Diabetes, 44(8):968-83, August 1995.

30. Levin, P.A., The DCCT Research Group: Effect of Intensive Diabetes Management on Macrovascular Events and Risk Factors in the Diabetes Control and Complications Trial. Am-J-Cardiol, 75(14):894-903, May 1995.

31. Pavlov, E., Caudill, J., **Levin, P.**, and Kaplan, P. of The Osteoporosis and Metabolic Bone Center, Baltimore, MD: Is pDEXA Useful Screening Test. Fourth Annual Scientific Meeting, January 15-18, 1998.

32. Levin, P.A., Soumai, M., Lee, F., Mersey, J.,Diabetes Division, Greater Baltimore Medical Center, Baltimore, MD, US, "Improvement of Brittle Diabetes Control After Switch to Insulin Glargine", Poster Presentation submitted to 18th International Diabetes Federation Congress, 2003.

33. Levin P1, Zhang Q2, Mersey J1, Lee F1, Bromberger L1, Bhushan M3, Jhaveri M4, Bhushan R3 1MODEL Clinical Research, Baltimore, MD, USA,2 sanofi aventis, Bridgewater, NJ, USA, 3 Metabolic Center of Louisiana Research Foundation, Baton Rouge, LA, USA,4Rutgers University, Piscataway, NJ, USA, "Glycemic Control with Insulin Glargine Plus Glulisine versus Premix in Real World Practices- A Randomized, Prospective, Observational Study" Poster presented at ISPOR 10th Annual European Congress, Dublin, Ireland, 2007.

34. Levin P1, Zhang Q2, Mersey J1, Lee F1, Bromberger L1, Bhushan M3, Jhaveri M4, Bhushan R 1MODELClinical Research, Baltimore, MD, USA, 2 sanofi aventis, Bridgewater, NJ, USA, 3 Metabolic Center of Louisiana Research Foundation, Baton Rouge, LA, USA, 4Rutgers University, Piscataway, NJ, USA, "Glycemic Control with Insulin Glargine Plus Glulisine versus Premix in Real World Practices- A Randomized, Prospective, Observational Study" Poster presented at EASD 44th Annual Meeting, Rome, Italy, 2008.

35. Levin P1, Danel A2, Bromberger L1, Choi J3, Mersey J1 1MODEL Clinical Research, Baltimore, MD, USA, 2 sanofi aventis, Paris, France, 3 Rutgers University, Piscataway, NJ, USA, " Glycemic Control and Cost – Effectiveness Following Initiation of Insulin Glargine or Detemir in Patients withType 2 Diabetes Mellitus – An Analysis of Electronic Medical Records". Poster presented at ISPOR 11th Annual European Congress, Athens, Greece, 2008.

36. Levin P1, Danel A2, Bromberger L1, Choi J3, Mersey J1 1MODEL Clinical Research, Baltimore, MD, USA, 2sanofi aventis, Paris, France, 3 Rutgers University, Piscataway, NJ, USA, "Glycemic Control and Cost-effectiveness Following Initiation of Insulin Glargine or Detemir in Patients With Type 2 Diabetes Mellitus- An Analysis of Electronic Medical Records". Poster presented at iHEA Congress, Beijing, China, July 2008.

37. Levin P., "The cost –effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics", Diabetes Obes Metab.,10 Suppl 2:66-75, July 2008.

38. Levin P1, Mersey J1, Zhou S2, Bromberger L1 1MODEL Clinical Research, Baltimore, MD, USA, 2 sanofi aventis, Bridgewater, NJ, USA, "Clinical Outcomes Using Single Vs. Combination Therapy with Glargine (GLA) or Exenatide (Ex)". Poster presented at ADA meeting, Orlando, FL, July 2010.

39. Levin P, Mersey J, Huang W MODEL Clinical Research, Baltimore, MD, USA, "PDB3 Long-Term Antiproteinuric Effect Of Aliskiren In Diabetic Patients With Persistent Albuminuria Despite Chronic Acei Or Arb Treatment" Poster presented at ISPOR 16th Annual International Meeting, Baltimore, MD, USA,May 2011.

40. Levin, P.A., Zhang, Q., Mersey, J.H., Lee, F.Y.G., Bromberger, L.A., Bhushan, M., Bhushan,R., Glycemic Control with Insulin Glargine Plus Insulin Glulisine vs. Premixed Insulin Analogs in Real World Practices- A Cost Effectiveness Study With Randomized Pragmatic Trial Design, Clinical Therapeutics, accepted May 2011.

41. Levin, P.A., Mersey, J.H., Zhou, S., Bromberger, L.A., Clinical Outcomes UsingLong-Term Combination Therapy With Insulin Glargine and Exenatide in Patients with Type 2 Diabetes, Endocrine Practice, accepted May 2011.

42. Yeh, Hsin-Chieh, Huang, Elbert S., **Levin, P.,** Liu, Su-Hsun, Brancati, Frederick L., The Challenges of Treatment Decisions in Older Diabetes Patients, Abstract presented at ADA meeting, San Diego, CA, June, 2011.

43. Levin, Philip, Wei, Wenhui, Wang, Li, Pan, Chunshen, Douglas, Damon, Baser, Onur, Clinical Characteristics and Outcomes in Patients with Type 2 Diabetes Adding Insulin Glargine to Exenatide or Exenatide to Insulin Glargine in a US managed Care Setting, Poster presented at the 47th EASD Annual Meeting, Lisbon Portugal, September, 2011.

44. Levin, P.A., Mersey, J.H., Zhou, S, Bromberger, L.A., Clinical Outcomes Using Long-Term Combination Therapy With Insulin Glargine and Exenatide in Patients with Type 2 Diabetes Mellitus, Endocrine Practice, 2012 Jan 1;18(1):17- 25.

45. Levin, P.A., Mersey, J.H., Bromberger, L.A., Renal and Blood Pressure Effects of Aliskiren in Diabetic Hypertensive Patients: A Real World Retrospective Pilot Study, Poster presented at the AACE 21st Annual Scientific And Clinical Congress, Philadelphia, PA, May 2012.

46. Levin, Philip, Wei, Wenhui, Vlajnic, Aleksandra, Pan, Chunshen, Xie Lin, Lin, Baser, Onur, Real-world Outcomes of Initiating Injectable Therapy With Insulin Glargine or Liraglutide Among Patients With Type 2 Diabetes, Poster presented at the ADA meeting, Philadelphia, PA, June 2012.

47. Baser, O., Zhou, S., Wei, W. , Ling, Z. , Xie, L. , **Levin, P.** Treatment Patterns and A1c Reduction After Adding a 3rd Agent to 2 Oral Antidiabetic Drugs (OADs), Poster presented at the 48th EASD Annual Meeting, Berlin Germany, October, 2012.

48. Levin, Philip, Zhou, Steve, Wei, Wenhui, Durden, Emily, Farr, Amanda M., Gill, Jasvinder, A Retrospective Study of Outcomes Associated With Initiation of Basal Insulin After Failing Oral Antidiabetic Drugs, Poster presented at the 2013 EASD meeting, Barcelona, Spain, September, 2013.

49. Chaudry, Zoobia W., **Levin, Philip**, Bromberger, Lee, Yeh, Hsin-Chieh, Diabetes Control in Older Patients in Primary Care Clinic vs. Endocrinology Clinic, Poster and Abstract presented at Mid Atlantic Regional SGIM meeting, New York, NY, March 2014 and the 37th Annual SGIM meeting, San Diego, CA, April 2014.

50. Levin, Philip, Wei, Wenhui , Buysman, L., Grabner, M., Chu, J., The INITIATOR study: real world treatment patterns and outcomes in patients with type 2 diabetes initiating insulin glargine or liraglutide, Oral presentation presented at EASD 2014, Vienna, Austria, September 2014.

51. Levin, Philip, Wei, Wenhui, Baser, O, Therapeutically interchangeable? A study of real world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data, Diabetes, Obesity and Metabolism - DOM12407, Accepted October, 2014.

52. Philip Levin, Steve Zhou, Tao Fan, Xue Song, Damion Nero, Brian Davis, Bong-Chul Chu, Comparing Treatment Intensification Approaches in Patients with T2D Uncontrolled on Basal Insulin: Adding Glucagon-like Peptide-1 Receptor Agonists vs. Adding Rapid-Acting Insulin or Increasing Basal Insulin Dose, Oral presentation presented at American Diabetes Association 76th Scientific Sessions, New Orleans, Louisiana, June, 2016.

53. Kathleen Lang, Hiep Nguyen, Huan Huang, Elise Kaufman, **Philip Levin**, Real-World treatment Responses from Electronic Medical Record (EMR) Data among Patients with Type 2 Diabetes (T2D) Receiving Basal Insulin either with Mealtime Insulin or Exenatide BID, by A1c Attainment Level and Baseline A1c, Poster presented at American Diabetes Association 76th Scientific Sessions, New Orleans, Louisiana, June, 2016.

54. Philip Levin, Tao Fan, Steve Zhou, Xue Song, Damion Nero, Brian Davis, Bong-Chul Chu, Clinical Outcomes of T2D Treatment Intensification Options vs. No Intensification in Patients on Basal Insulin Treatment Not Meeting A1c Goals, Poster presented at American Diabetes Association 76th Scientific Sessions, New Orleans, Louisiana, June, 2016.

55. Lee Kallenbach, Fen Ye, Tao Fan, Wenli Hu, **Philip A. Levin**, Predictors and Clinical Outcomes of Treatment Intensification in Patients (Pts) with T2D Uncontrolled on Basal Insulin (BI) in Real-World Settings, Oral presentation at American Diabetes Association 77th Scientific Sessions, San Diego, California, June 2017.

56. Philip Levin, Lee A. Bromberger, Effective Treatment of T2D Patients Uncontrolled on Multiple Diabetes Medications by Adding Afrezza Ultra-Rapid Insulin, Poster presented at American Diabetes Association 78th Scientific Sessions, San Francisco, California, June, 2019.